Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach

NCT ID: NCT00020761

Last Updated: 2020-08-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 51 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2000-04-30
• Study Completion Date: 2005-08-31

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining irinotecan and paclitaxel in treating patients who have metastatic or recurrent cancer of the esophagus or stomach.

Detailed Description

OBJECTIVES:

• Determine the antitumor activity of irinotecan and paclitaxel in patients with metastatic or recurrent adenocarcinoma of the esophagus or stomach.
• Determine the toxic effects of this regimen in these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to diagnosis (adenocarcinoma of the esophagus, gastroesophageal junction, or gastric cardia vs adenocarcinoma of the rest of the stomach).

Patients receive irinotecan IV over 90 minutes followed by paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.

Patients are followed at 30 days and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 26-54 patients (13-27 per stratum) will be accrued for this study.

Conditions

Esophageal Cancer; Gastric Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Gastro Esophogeal cohort

Patients with adenocarcinoma of the esophagus, gastroesophageal (GE) junction and gastric cardia (GE cohort)

The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.

Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.

Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks.

Group Type: EXPERIMENTAL

irinotecan hydrochloride

Intervention Type: DRUG

The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.

Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.

paclitaxel

Intervention Type: DRUG

The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.

Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks.

Distal Stomach cohort

Patients with adenocarcinoma of the rest of the stomach (Distal Stomach cohort)

The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.

Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.

Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks.

Group Type: EXPERIMENTAL

irinotecan hydrochloride

Intervention Type: DRUG

The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.

Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.

paclitaxel

Intervention Type: DRUG

The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.

Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks.

Interventions

irinotecan hydrochloride

The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.

Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.

Intervention Type: DRUG

paclitaxel

The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.

Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with histologic proof of adenocarcinoma of the esophagus (including GE junction) or adenocarcinoma of the stomach will be eligible.
• Location of the tumor for assignment to study will be determined by prior endoscopy or barium contrast study.
• Patients must have either metastatic or recurrent cancer.
• Patients must have bidimensionally measurable disease, as defined in Section 8.4.1.1, page 16. Mediastinal or hilar lymph nodes assessed by CT or MRI scans must be at least 2 cm in the largest dimension to be considered measurable.
• Prior limited radiation therapy is permitted. Prior radiotherapy must not have included major bone marrow containing areas (pelvis, lumbar spine), or contained the single evaluable lesion in a radiation field. A recovery period of at least 4 weeks after completion of radiotherapy is required prior to study treatment.
• Patients must have an anticipated life expectancy of at least 12 weeks.
• Patients must have a performance status of 0 or 1 on the ECOG performance scale.
• Patients must be > 18 years old.
• Patients must give written informed consent prior to enrollment.
• Patients should have adequate organ function defined as follows: Absolute granulocytes > 1,500/mm3 and platelets > 100,000/mm3; serum bilirubin < 1.5 mg/dL and SGOT < 3X upper limit of institutional norm; and serum creatinine < 1.5 mg/dL.
• Patients must have recovered from recent surgery. One week must have elapsed from the time of a minor surgery and 3 weeks from major surgery.

Exclusion Criteria

• Patients who have received more than one prior chemotherapy regimen or immunotherapy for metastatic disease. Prior 5-FU alone as an adjuvant therapy or radiosensitizer is not counted. Patients must have an interval of 4 weeks from prior chemotherapy or immunotherapy with full recovery.
• Patients receiving concurrent chemotherapy, immunotherapy, or radiotherapy.
• Patients who are potentially curable with a chemotherapy, radiotherapy, surgery, or any combination of the above.
• Patients with known brain metastases.
• Patients with a history of seizures or are receiving phenytoin, phenobarbital, or other antiepileptic prophylaxis.
• Pregnant or lactating women. All women of childbearing potential must have a negative pregnancy test prior to entry into the study. All patients of procreative potential must be advised of the importance of avoiding pregnancy and using appropriate methods of contraception while participating in this investigational trial.
• Patients with serious intercurrent infections, or any other concurrent disease which, in the investigator's judgment, would make the patient inappropriate for entry into this study.
• Patients with psychiatric disorders rendering them incapable of complying with the requirements of the protocol.
• Patients with osseous metastasis as only site of disease.
• Patients with any concurrent active malignancy other than non-melanoma skin cancers or carcinoma-in-situ of the cervix. Patients with previous malignancies but without evidence of disease for > 5 years will be allowed to enter the trial.
• Patients with known Gilbert's syndrome.
• Patients who have a significant clinical neuropathy of greater than grade 2.
• Patients with unstable angina, a history of myocardial infarction within the previous 6 months, or current clinical evidence of congestive heart failure. Patients taking medication for congestive heart failure and showing no clinical signs or symptoms are eligible.
• Patients who have previously received a taxane or campthothecin
• Patients who have received any investigational therapy within the previous 4 weeks.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jonsson Comprehensive Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

UCLA

Principal Investigators

Joel R. Hecht, MD

Role: STUDY_CHAIR

Jonsson Comprehensive Cancer Center

Locations

USC/Norris Comprehensive Cancer Center and Hospital

Los Angeles, California, United States

Jonsson Comprehensive Cancer Center, UCLA

Los Angeles, California, United States

Robert H. Lurie Comprehensive Cancer Center, Northwestern University

Chicago, Illinois, United States

OHSU Cancer Institute

Portland, Oregon, United States

Countries

United States

Other Identifiers

UCLA-0001048

Identifier Type: -

Identifier Source: secondary_id

NCI-G01-1957

Identifier Type: -

Identifier Source: secondary_id

CDR0000068711

Identifier Type: -

Identifier Source: org_study_id